London, 2019-03-05 - NBE-Therapeutics will present at the 9th World ADC Congress Europe in London

Ulf Grawunder, CEO of NBE-Therapeutics, has been invited to present an update on NBE-Therapeutics' next-generation iADC platform and the company's lead iADC, NBE-002, targeting ROR1

Read more

San Diego, USA, 2019-03-04 - NBE-Therapeutics invited to present at Terrapinn's Americas Antibody Congress

Roger Beerli, CSO of NBE-Therapeutics, is invited to provide an update on NBE-Therapeutics' ADC development activities at Terrapinn's Americas Antibody Congress, which is part of the 2019 Festival of Biologics USA

Read more

San Diego, USA, 2018-12-11 - NBE-Therapeutics was invited to present at KNect365's 2018 Antibody Engineering & Therapeutics Conference

Roger Beerli, CSO of NBE-Therapeutics, was invited to provide an update on NBE-Therapeutics' ADC development activities at KNect365's 2018 Antibody Engineering & Therapeutics Conference in San Diego, USA.

Read more

Lisbon, 2018-11-13 - NBE-Therapeutics was invited to present at CHI's 10th Annual PEGS Europe Protein & Antibody Engineering Summit

Roger Beerli, CSO of NBE-Therapeutics, and Rémy Gébleux, Scientist II, were invited to provide an update on NBE-Therapeutics' ADC development activities at CHI's 10th Annual PEGS Europe Protein & Antibody Engineering Summit in Lisbon.

Read more

Basel, 2018-10-31 - NBE-Therapeutics was invited to present at Terrapinn's 2018 High-potency API congress

Roger Beerli, CSO of NBE-Therapeutics, was invited to provide an update on NBE-Therapeutics ADC development activities at Terrapinn's High-potency API congress, which is part of the 2018 Festival of Biologics

Read more

next >